rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Comprehensive Review: GLP-1, GIP, and Glucagon Receptor Therapies for Metabolic Health

RPEP-154312026Khan, Mohammed Shareef; Bhutani, Utkarsh; Venugopal, Hariharan; Saini, Anuj Kumar; Naidu, Venkat Ramana; Kollipara, Sivacharan
evidence
The takeaway

Comprehensive review of single, dual, and triple incretin receptor agonists covering GLP-1, GIP, and glucagon pathways for metabolic disease management with evolving clinical evidence.

Single → dual → triple

Incretin therapy is evolving from one receptor target to three — each generation providing more comprehensive metabolic benefit

What the researchers found

Comprehensive coverage of GLP-1, GIP, and glucagon receptor agonists: single (semaglutide), dual (tirzepatide), and triple (retatrutide) approaches with distinct metabolic profiles and expanding clinical evidence.

Why it matters

Understanding how single, dual, and triple agonists differ enables precision prescribing for individual metabolic profiles.

How the study worked

Comprehensive review of incretin receptor therapies covering pharmacology, clinical evidence, and therapeutic positioning.

What this study cannot tell us

Triple agonists are early clinical. Long-term combination safety unknown.

How to read the evidence

Comprehensive review of approved and pipeline therapies.

When this study was published

Published in 2025.

The bigger picture

The evolution from single to triple agonists represents iterative metabolic drug engineering — each generation more comprehensive than the last.

Questions still open

  • Will all patients need triple agonists, or are single/dual sufficient for most?
  • Is cost-effectiveness better with triple vs dual agonists?
  • Will quadruple agonists emerge?

Common questions

What is the difference between GLP-1 drugs and newer options?
GLP-1 drugs (semaglutide) target one receptor. Tirzepatide targets two (GLP-1+GIP). Retatrutide targets three (GLP-1+GIP+glucagon). Each additional target provides additional metabolic benefit.
Will I need the newest triple agonist?
Not necessarily. Single GLP-1 drugs work well for many patients. Dual and triple agonists may be reserved for those needing maximum weight loss or metabolic improvement.

Read the original research

Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP-1, GIP, and Glucagon Agonists.

Journal of peptide science : an official publication of the European Peptide Society, 32(2), e70083

View on PubMed ↗Publisher’s paper ↗

Citation

Khan, Mohammed Shareef; Bhutani, Utkarsh; Venugopal, Hariharan; Saini, Anuj Kumar; Naidu, Venkat Ramana; Kollipara, Sivacharan. (2026). Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP-1, GIP, and Glucagon Agonists.. Journal of peptide science : an official publication of the European Peptide Society, 32(2), e70083. https://doi.org/10.1002/psc.70083